title: The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
abstract: In recent years, the genetic factor has become one of the important predisposing factors of nephropathy susceptibility. There is a high incidence of nephropathy in CCVd. The CYP2C19 enzyme metabolizes most the drugs, including proton pump inhibitors commonly used medicines to treat CCVd, CYP2C19 genetic polymorphisms is association with multi-pathogenesis factors of nephropathy. The purpose of the study is to reveal the association between CYP2C19 genotype and the susceptibility of nephropathy in the CCVd patients. The study is composed of 623 samples from CCVd treated by anticoagulation. The patients were studied, including CCVd with hyperuricemia, coronary heart disease, diabetes, and other complication. Biochemical tests and CYP2C19 variants measurements were performed by the gene chip method. The association among CYP2C19 variants, complications, and nephropathy was analyzed in the CCVd. There is no correlation between nephropathy and complications in CCVd. In hyperuricemia, coronary heart disease and diabetes groups, the differences of renal function tests were significant between CYP2C19 mutant (P < 0.05). The nephropathy risk of wild genotype is 3.288 times higher than of mutation genotype in hyperuricemic group, 1.928 times higher than mutation genotype in coronary heart disease group, and 5.248 times higher than CYP2C19 mutation genotype in the diabetic group. There was significant correlation between the CYP2C19 wild type and the nephropathy susceptibility in CCVd patients. The CYP2C19 gene plays a potential maker to evaluate nephropathy in CCVd patients. We deduced that identification of CYP2C19 gene type may benefit for reducing and avoiding nephropathy caused by abnormal metabolism function in CCVd patients.
authors.affiliation: Department of Clinical Laboratory Department of Cardio Vascular, Chengdu Military General Hospital, Chengdu, People's Republic of China.
authors.forename: Kai
authors.initials: K
authors.lastname: Chang
authors.forename: Zhongyong
authors.initials: Z
authors.lastname: Jiang
authors.forename: Chenxia
authors.initials: C
authors.lastname: Liu
authors.forename: Junlong
authors.initials: J
authors.lastname: Ren
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Jie
authors.initials: J
authors.lastname: Xiong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics*; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D033461:Hyperuricemia / Q000150:complications; D007668:Kidney / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009154:Mutation; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy / Q000235:genetics*
chemical_list: D000925:Anticoagulants; D005819:Genetic Markers; D065731:Cytochrome P-450 CYP2C19